Skip to main content

Advertisement

Log in

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Till now, little is known about the effects of chemotherapy on the immunity of cancer patients and the ideal timing (“window” period) for immunotherapy combined with chemotherapy. In this study, we addressed the immunogenicity of apoptotic ovarian cancer cells induced by paclitaxel and carboplatin, the immunologic aspects in ovarian cancer patients under chemotherapy, and the CTL response when CD8+ T cells were stimulated with tumor antigen in the “window” period. The immunogenicity of apoptotic ovarian cancer cells was detected first. Then, blood samples from each ovarian cancer patient were obtained before (S0) and at days 5–7 (S1), days 12–14 (S2) and days 25–28 (S3) after chemotherapy. The proportions of immunocyte subsets and the function of NK cells were studied. We found that apoptotic ovarian cancer cells elicited a powerful CTL response with antitumor activity in vitro. The proportions of CD3+ T cells, CD4+ T cells and the ratio of CD4+ to CD8+ cells did not change significantly on S1, S2 and S3, compared to S0, whereas the percentage of Treg cells decreased remarkably on S2. The proportions of Th1, Tc1, CD45RO memory T, NKT cells and the ratio of Tc1 to Tc2 cells increased significantly on S2. IFN-γ secreting CD8+ T cells also increased remarkably on S2, especially when CD8+ T cells were stimulated with autologous tumor antigen. From our point of view, chemotherapy induces temporary immune reconstitution and augments anti-tumor immune response. It is probable that the “window” period of days 12–14 after chemotherapy provides the best opportunity for immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

    Article  PubMed  Google Scholar 

  2. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3–10

    Article  CAS  PubMed  Google Scholar 

  3. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73

    Article  CAS  PubMed  Google Scholar 

  4. Weiner HL, Cohen JA (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 8:142–154

    Article  CAS  PubMed  Google Scholar 

  5. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822

    CAS  PubMed  Google Scholar 

  6. Chan OT, Yang LX (2000) The immunological effects of taxanes. Cancer Immunol Immunother 49:181–185

    Article  CAS  PubMed  Google Scholar 

  7. Skoberne M, Beignon AS, Larsson M, Bhardwaj N (2005) Apoptotic cells at the crossroads of tolerance and immunity. Curr Top Microbiol Immunol 289:259–292

    Article  CAS  PubMed  Google Scholar 

  8. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277–288

    Article  CAS  PubMed  Google Scholar 

  9. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH (1995) Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 6:3–16

    Article  CAS  PubMed  Google Scholar 

  10. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61

    Article  CAS  PubMed  Google Scholar 

  11. Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G (2007) Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med 85:1069–1076

    Article  CAS  PubMed  Google Scholar 

  12. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57:1579–1587

    Article  CAS  PubMed  Google Scholar 

  13. Flick MB, O’Malley D, Rutherford T, Rodov S, Kamsteeg M, Hao XY, Schwartz P, Kacinski BM, Mor G (2004) Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig 11:252–259

    Article  CAS  PubMed  Google Scholar 

  14. Boisteau O, Gautier F, Cordel S, Henry F, Harb J, Douillard JY, Vallette FM, Meflah K, Gregoire M (1997) Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 2:403–412

    Article  CAS  PubMed  Google Scholar 

  15. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M (1999) Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 59:3329–3332

    CAS  PubMed  Google Scholar 

  16. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83–93

    Article  CAS  PubMed  Google Scholar 

  17. Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A (1999) Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 5:445–454

    CAS  PubMed  Google Scholar 

  18. Steinman RM, Mellman I (2004) Immunotherapy: bewitched, bothered, and bewildered no more. Science 305:197–200

    Article  CAS  PubMed  Google Scholar 

  19. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727

    Article  CAS  PubMed  Google Scholar 

  20. Lake RA, van der Most RG (2006) A better way for a cancer cell to die. N Engl J Med 354:2503–2504

    Article  CAS  PubMed  Google Scholar 

  21. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701

    Article  CAS  PubMed  Google Scholar 

  22. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G (2007) Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. Cancer Res 67:7941–7944

    Article  CAS  PubMed  Google Scholar 

  23. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Robe J, Endres S, Eigler A (2002) Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 62:2347–2352

    CAS  PubMed  Google Scholar 

  24. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL (2000) Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60:3542–3549

    CAS  PubMed  Google Scholar 

  25. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM (1998) Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188:2163–2173

    Article  CAS  PubMed  Google Scholar 

  26. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89

    Article  CAS  PubMed  Google Scholar 

  27. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N (1998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188:1359–1368

    Article  CAS  PubMed  Google Scholar 

  28. van der Most RG, Currie AJ, Robinson BW, Lake RA (2008) Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ 15:13–20

    Article  PubMed  Google Scholar 

  29. Binder RJ, Srivastava PK (2005) Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 6:593–599

    Article  CAS  PubMed  Google Scholar 

  30. Ito N, Nakamura H, Tanaka Y, Ohgi S (1999) Lung carcinoma: analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 85:2359–2367

    Article  CAS  PubMed  Google Scholar 

  31. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC (2001) Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 167:2972–2978

    CAS  PubMed  Google Scholar 

  32. Kemp RA, Ronchese F (2001) Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 167:6497–6502

    CAS  PubMed  Google Scholar 

  33. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R (2004) Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 101:16004–16009

    Article  CAS  PubMed  Google Scholar 

  34. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R (2003) Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4:1191–1198

    Article  CAS  PubMed  Google Scholar 

  35. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H (2007) Targeting CD4+CD25+FoxP3+ regulatory T cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 8:1002–1008

    CAS  PubMed  Google Scholar 

  36. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L (2005) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T-cell proliferation. J Exp Med 202:919–929

    Article  CAS  PubMed  Google Scholar 

  37. Brode S, Cooke A (2008) Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 28:109–126

    CAS  PubMed  Google Scholar 

  38. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end-stage cancer patients. Cancer Immunol Immunother 56:641–648

    Article  CAS  PubMed  Google Scholar 

  39. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336–344

    Article  CAS  PubMed  Google Scholar 

  40. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905–4913

    CAS  PubMed  Google Scholar 

  41. Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z (2005) Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res 65:7000–7006

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 30801363) and the Foundation of Shanghai Municipal Education Commission (08YZ43). We are very grateful to all patients who participated in this trial.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wen Di.

Additional information

X. Wu and Q. Feng contributed equally to this work and should be considered as co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, X., Feng, QM., Wang, Y. et al. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother 59, 279–291 (2010). https://doi.org/10.1007/s00262-009-0749-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-009-0749-9

Keywords

Navigation